These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 19858422)

  • 1. Letter by Ala-Korpela et al regarding article, "Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women".
    Ala-Korpela M; Soininen P; Savolainen MJ
    Circulation; 2009 Oct; 120(17):e149; author reply e150. PubMed ID: 19858422
    [No Abstract]   [Full Text] [Related]  

  • 2. Letter by Lund et al regarding article, "fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events".
    Lund SS; Vaag AA; Jensen T
    Circulation; 2009 Apr; 119(13):e384; author reply e385. PubMed ID: 19349329
    [No Abstract]   [Full Text] [Related]  

  • 3. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy.
    Jeyarajah EJ; Cromwell WC; Otvos JD
    Clin Lab Med; 2006 Dec; 26(4):847-70. PubMed ID: 17110242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Diagnosis of high risk of heart disease among asymptomatic persons].
    Holme I; Hjermann I
    Tidsskr Nor Laegeforen; 2002 Sep; 122(21):2132-3. PubMed ID: 12555653
    [No Abstract]   [Full Text] [Related]  

  • 5. Advanced lipoprotein testing: recommendations based on current evidence.
    Lau JF; Smith DA
    Endocrinol Metab Clin North Am; 2009 Mar; 38(1):1-31. PubMed ID: 19217510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Should advanced lipoprotein testing be used in clinical practice?
    Stein JH; McBride PE
    Nat Clin Pract Cardiovasc Med; 2006 Dec; 3(12):640-1. PubMed ID: 17122792
    [No Abstract]   [Full Text] [Related]  

  • 7. [Apolipoproteins are better risk markers than conventional lipids].
    Walldius G; Holme I; Jungner I
    Lakartidningen; 2007 Sep 12-18; 104(37):2612-3. PubMed ID: 17970399
    [No Abstract]   [Full Text] [Related]  

  • 8. Lipids and Lipoproteins in Risk Prediction.
    Hadjiphilippou S; Ray KK
    Cardiol Clin; 2018 May; 36(2):213-220. PubMed ID: 29609750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum lipids, lipoproteins and apolipoproteins in untreated essential hypertension.
    Donma O; Donma MM; Kahraman D; Uygur H; Sagliker Y
    J Hum Hypertens; 1993 Jun; 7(3):311-3. PubMed ID: 8345503
    [No Abstract]   [Full Text] [Related]  

  • 10. Letter by Bell and O'keefe regarding article, "Use of alternative thresholds defining insulin resistance to predict incident type 2 diabetes mellitus and cardiovascular disease".
    Bell DS; O'Keefe JH
    Circulation; 2008 Sep; 118(11):e156; author reply e157. PubMed ID: 18779451
    [No Abstract]   [Full Text] [Related]  

  • 11. Lp(a) lipoprotein, vascular disease, and mortality in the elderly.
    Kovesdy CP
    N Engl J Med; 2004 Mar; 350(11):1150-2; author reply 1150-2. PubMed ID: 15017680
    [No Abstract]   [Full Text] [Related]  

  • 12. [Predictive value of lipid and lipoprotein changes in ischemic cerebral vascular accidents].
    González López JJ; Cañadillas Hidalgo I; Muñoz Gomariz E; Añón Barbudo J; Sánchez Guijo P
    Rev Clin Esp; 1987 Oct; 181(5):239-41. PubMed ID: 3685550
    [No Abstract]   [Full Text] [Related]  

  • 13. Detection of malignant tumors by nuclear magnetic resonance spectroscopy of plasma.
    N Engl J Med; 1987 May; 316(22):1411-5. PubMed ID: 3574419
    [No Abstract]   [Full Text] [Related]  

  • 14. Hyperlipidaemia and cardiovascular disease: apolipoprotein measurements and metabolic syndrome as predictors of cardiovascular risk.
    Deans KA; Dominiczak MH
    Curr Opin Lipidol; 2008 Dec; 19(6):624-6. PubMed ID: 18957887
    [No Abstract]   [Full Text] [Related]  

  • 15. Letter by Sniderman et al Regarding Article, "Comparison of Conventional Lipoprotein Tests and Apolipoproteins in the Prediction of Cardiovascular Disease".
    Sniderman AD; Thanassoulis G; Pencina M
    Circulation; 2019 Dec; 140(24):e822-e823. PubMed ID: 31815544
    [No Abstract]   [Full Text] [Related]  

  • 16. Response by Welsh et al to Letter Regarding Article, "Comparison of Conventional Lipoprotein Tests and Apolipoproteins in the Prediction of Cardiovascular Disease".
    Welsh P; Welsh C; Pell J; Sattar N
    Circulation; 2019 Dec; 140(24):e824-e825. PubMed ID: 31815545
    [No Abstract]   [Full Text] [Related]  

  • 17. Apolipoproteins: promising biomarkers for cardiovascular risk prediction.
    Romero-Corral A; Somers VK; Lopez-Jimenez F
    J Intern Med; 2008 Jul; 264(1):1-3. PubMed ID: 18554334
    [No Abstract]   [Full Text] [Related]  

  • 18. Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy.
    Otvos JD
    Clin Lab; 2002; 48(3-4):171-80. PubMed ID: 11934219
    [No Abstract]   [Full Text] [Related]  

  • 19. Diet quality, front-of-pack labeling, and lipoprotein particle profiles.
    Haslam DE; Mora S
    Atherosclerosis; 2024 Aug; 395():117600. PubMed ID: 38853066
    [No Abstract]   [Full Text] [Related]  

  • 20. The prognostic implications of cardiovascular magnetic resonance.
    Flett AS; Westwood MA; Davies LC; Mathur A; Moon JC
    Circ Cardiovasc Imaging; 2009 May; 2(3):243-50. PubMed ID: 19808599
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.